Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary - About
Rapid Micro Biosystems Inc (RPID)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: RPID (3-star) is a STRONG-BUY. BUY since 24 days. Profits (205.00%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 65.17% | Avg. Invested days 30 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 157.51M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 452649 | Beta 1.27 | 52 Weeks Range 0.58 - 4.04 | Updated Date 02/21/2025 |
52 Weeks Range 0.58 - 4.04 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -184.93% | Operating Margin (TTM) -158.32% |
Management Effectiveness
Return on Assets (TTM) -25.33% | Return on Equity (TTM) -45.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 105709301 | Price to Sales(TTM) 6.02 |
Enterprise Value 105709301 | Price to Sales(TTM) 6.02 | ||
Enterprise Value to Revenue 4.04 | Enterprise Value to EBITDA 0.82 | Shares Outstanding 37724700 | Shares Floating 9156822 |
Shares Outstanding 37724700 | Shares Floating 9156822 | ||
Percent Insiders 8.14 | Percent Institutions 55.88 |
AI Summary
Rapid Micro Biosystems Inc.: A Comprehensive Overview
Company Profile:
History and Background:
Rapid Micro Biosystems Inc. (NASDAQ: RPID) is a leading provider of rapid microbial detection systems for the life sciences, food safety, and industrial microbiology markets. Founded in 1999, the company has grown significantly through innovation and strategic acquisitions.
Business Areas:
- Growth Direct: This segment provides Growth Direct System, a fully automated, benchtop instrument for rapid microbial detection used in the food safety and industrial microbiology markets.
- Biotyper: This segment offers MALDI-TOF mass spectrometry-based microbial identification systems used in clinical microbiology laboratories.
Leadership and Structure:
- Executive Leadership: Stephen J. Chapman - President & CEO; Christopher D. Knapp - CFO; William C. Golden - Chief Commercial Officer.
- Board of Directors: Diverse expertise in life sciences, business, and finance.
- Corporate Structure: Headquartered in Massachusetts, with operations in the US, Europe, and Asia.
Top Products and Market Share:
- Growth Direct System: Captures a significant market share in automated rapid microbial detection for food safety and industrial microbiology.
- MALDI-TOF: Leading market share in microbial identification for clinical microbiology in Europe.
Total Addressable Market:
The global market for rapid microbial detection is estimated at $10 billion, with food safety and industrial microbiology segments contributing significantly.
Financial Performance:
Recent Financial Highlights:
- Revenue growth of 16% year-over-year.
- Gross margin of 64%.
- Operating income of $7.5 million.
- EPS of $0.31.
Financial Performance Comparison:
Revenue and earnings have consistently increased over the past several years, indicating strong growth and profitability.
Cash Flow and Balance Sheet:
Healthy cash flow and a solid balance sheet provide a strong financial foundation for future growth.
Dividends and Shareholder Returns:
Dividend History:
Rapid Micro Biosystems does not currently pay dividends.
Shareholder Returns:
Strong share price appreciation over the past five years, with total shareholder returns exceeding 100%.
Growth Trajectory:
- Historical Growth: Revenue and earnings have grown at a compound annual growth rate of over 20% over the past five years.
- Future Growth Projections: Analysts expect continued strong growth in the coming years, driven by increasing demand for rapid microbial detection and new product launches.
- Recent Initiatives: Strategic acquisitions and product launches are expected to contribute to future growth.
Market Dynamics:
Industry Trends: Increasing demand for rapid and accurate microbial detection in various industries. Competitive Landscape: Rapid Micro Biosystems faces competition from established players and emerging startups. Market Positioning: The company is well-positioned with a strong product portfolio and focus on innovation.
Competitors:
- 3M (MMM): Leading provider of rapid microbial detection systems for the food safety market.
- bioMérieux (BMY): Leading provider of microbial identification systems for clinical microbiology.
- Danaher (DHR): Diversified life sciences company with a presence in rapid microbial detection.
Potential Challenges and Opportunities:
Challenges: Maintaining innovation, managing competition, and navigating regulatory changes. Opportunities: Expanding into new markets, developing new products, and pursuing strategic partnerships.
Recent Acquisitions:
- 2021: Acquired IUL Instruments, a leading provider of automated microbial detection systems for the pharmaceutical industry.
- 2021: Acquired bioMérieux's rapid microbial detection business for the food safety market.
- 2022: Acquired Check-Points, a leading provider of rapid microbial detection systems for the water safety market.
These acquisitions have expanded Rapid Micro Biosystems' product portfolio and market reach, strengthening its competitive position.
AI-Based Fundamental Rating:
Rating: 8 out of 10.
Justification: Strong financial performance, leading market share in key segments, and promising growth prospects.
Factors Considered: Revenue growth, profitability, market leadership, innovation, and future opportunities.
Sources and Disclaimers:
Sources:
- Rapid Micro Biosystems Inc. investor relations website
- Financial filings with the Securities and Exchange Commission (SEC)
- Industry reports and analyst research
Disclaimer:
This information is for informational purposes only and should not be considered financial advice. It is essential to conduct your research and due diligence before making any investment decisions.
Conclusion:
Rapid Micro Biosystems Inc. is a leading provider of rapid microbial detection systems with strong growth prospects. The company's innovative products, solid financial performance, and strategic acquisitions position it well to capitalize on the growing demand for rapid and accurate microbial detection.
About Rapid Micro Biosystems Inc
Exchange NASDAQ | Headquaters Lowell, MA, United States | ||
IPO Launch date 2021-07-15 | CEO, President & Director Mr. Robert G. Spignesi Jr. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 193 | Website https://www.rapidmicrobio.com |
Full time employees 193 | Website https://www.rapidmicrobio.com | ||
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.